N/A N=15 Clinical Evaluation of CelluTite Treatment
Cellulite of Thighs
Primary: Change in Cellulite Score Rated According to Cellulite Severity Scale (Dimples) — 2.45 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=100 Dapagliflozin Effects on Epicardial Fat
Type 2 Diabetes
Primary: Epicardial Fat Thickness — 8.6; 8.0; 7.2; 7.4 mm
Phase 4 N=98 The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa
Parkinson Disease
Primary: Change From Baseline to Week 18 in Parkinson's Disease Sleep Scale 2nd Version (PDSS-2) Total Score — -13.7; -14.4 Score on a scale — p=0.688
Phase 2 N=4 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
Familial Partial Lipodystrophy
Primary: Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27) — -59.9 percent change
Phase 4 N=74 A Trial Comparing Single Intra-op Dose of Methadone Versus Placebo in Patients Undergoing Spine Surgery
Thoracolumbar Scoliosis
Primary: Opioid Usage — 0.41; 0.47; 0.58; 0.55 mg/kg
N/A N=19 Dopamine Responsivity in Gamblers
Pathological Gambling
Primary: Correlation Between the Impulsive Choice Ratio and Baseline Impulsivity, as Measured With the Barratt Impulsiveness Scale, Non-planning Subscale — -0.5 Correlation…
N/A N=111 COOL AMI EU Pivotal Trial to Assess Cooling as an Adjunctive Therapy to PCI In Patients With Acute MI (Phase A)
Acute Myocardial Infarction
Primary: Relative Reduction of 20% in Mean Anterior Myocardial Infarct Size as Determined by Cardiac Magnetic Resonance (cMR) Imaging at 4-6 Days Post Infarct in the Test Arm…
Phase 2 N=106 Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
Stage III Non-small Cell Lung Cancer
Primary: Disease-Control Rate — 89 Participants
Phase 3 N=112 A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
Hypoglycemia · Diabetes Mellitus, Type 1
Primary: Percentage of Patients With ADA — 0; 0; 56; 54 Participants
Phase 2 N=170 SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer
Pancreatic Cancer
Primary: The Median Survival Time Will be Determined. — 12.8; 14.9 months
N/A N=73 Zenith® Dissection Clinical Trial
Aortic Dissection
Primary: Number of Participants With Freedom From Major Adverse Events — 48 participants
Phase 3 N=142 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy
Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy
Primary: Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score — .7971 proportion of subjects
N/A N=197 Evaluation the Effectiveness of a Telemonitoring Program in a Cohort of COPD Patient With Frequent Readmissions
COPD
Primary: Number of Hospitalizations for COPD Exacerbation (eCOPD) — 1.1; 2.8 number of hospital admissions
Phase 2 N=54 Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy
Hematologic Malignancies
Primary: Number of Nucleated Cells Collected Within the Apheresis Products — 5.7; 3.8 cells x10e10
Phase 2 N=76 Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms
Post-menopausal Vasomotor Symptoms
Primary: Maximum Observed Plasma Concentration (Cmax) of BAY3427080 — 502.62; 731.69; 911.48; 1576.01 ng/mL